Shanghai Kaibao Pays $20 Million for 20% Stake in Shanghai Yizhong Biotech

Shanghai Kaibao Pharmaceutical invested $20 million in Shanghai Yizhong Biotech, a company developing a coated form of the cancer drug paclitaxel. Kaibao owns a 20% stake in Yizhong following the transaction. Yizhong's lead product, currently approved for clinical trials, is an injected form of paclitaxel micelles, a Class 5 biologic drug, aimed at improving delivery of paclitaxel to patients with lung cancer. More details.... Stock Symbol: (SHZ: 300039) Share this with colleagues: // //